HRTXHealthcare · BiotechnologyThe 2 Wall Street analysts covering Heron Therapeutics, Inc. hold a median 12-month price target of $7 — +2097.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Heron Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (95): The business earns solid, repeatable profits on what it owns.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2097.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $2.00 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 June 2026 | Needham | Downgrade | Hold | — |
| 3 June 2026 | Needham | Downgrade | Hold | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2025 | Needham | Maintains | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Needham | Reiterates | Buy | — |
| 4 Dec 2024 | Needham | Reiterates | Buy | — |
| 13 Nov 2024 | Needham | Maintains | Buy | — |
| 25 Sept 2024 | Needham | Reiterates | Buy | — |
| 7 Aug 2024 | Needham | Reiterates | Buy | — |
| 13 June 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 16 May 2024 | Needham | Reiterates | Buy | — |
| 8 May 2024 | Needham | Reiterates | Buy | — |
| 23 Apr 2024 | Capital One | Initiates | Overweight | — |
| 11 Apr 2024 | Needham | Reiterates | Buy | — |
| 13 Mar 2024 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HRTX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 86% of US stocks
Cheaper than 10% of US stocks
Cheaper than 88% of US stocks
Higher than 30% of US stocks
Higher than 82% of US stocks
Higher than 27% of US stocks
Higher than 15% of US stocks
Higher than 10% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Heron Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Heron Therapeutics' Q2 2026 earnings call. The item presents the company's earnings call transcript for the quarter.
Why it matters — An HRTX watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 financial results and management commentary.
Heron Therapeutics reported a Q2 loss of $0.03 per share, wider than the Zacks Consensus Estimate of a $0.02 loss and matching the year-ago quarter's $0.02 per-share loss. Revenue also lagged expectations.
Why it matters — The wider-than-expected quarterly loss and revenue miss signal the company's near-term financial performance fell short of analyst forecasts.
Heron Therapeutics reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the same period last year. Management said sales of its key products came in below its internal expectations.
Why it matters — The revenue growth is offset by management's disclosure that key product sales fell short of internal expectations, which is relevant to HRTX watchers assessing the company's performance.
Heron Therapeutics announced it will release its second quarter 2026 financial results and host a conference call on August 10, 2026.
Why it matters — The call and webcast will provide investors and analysts with updates on Heron's quarterly financial performance and recent business highlights.
The 2 Wall Street analysts covering Heron Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Heron Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Heron Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Heron Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +2097.1% from the last close, and Ticker Nerd's factor model ranks Heron Therapeutics, Inc. 44 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Heron Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
Heron Therapeutics, Inc. returned -75.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Heron Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutic treatments to address unmet medical needs.
The most recent item we track (Seeking Alpha, 10 Aug 2026): "Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Heron Therapeutics' Q2 2026 earnings call. The item presents the company's earnings call transcript for the quarter.
Heron Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutic treatments to address unmet medical needs. The company's primary focus is on improving the lives of patients suffering from cancer and pain, aiming to enhance the efficacy and safety of treatments in these areas. Heron Therapeutics is notable for its work on innovative drug delivery methods, such as extended-release formulations that aim to optimize the therapeutic effects of medications while minimizing side effects. With a strong emphasis on clinical development, Heron operates at the intersection of pharmacology and patient care, pushing advancements particularly within oncology and postoperative pain management fields. The company’s contributions are significant within the healthcare sector, as they provide potential breakthroughs in the treatment paradigms of serious and prevalent conditions. Furthermore, Heron Therapeutics' innovations can influence both clinical practices and healthcare expenditures by potentially offering alternatives that improve patient outcomes and reduce the need for ongoing intervention.
CEO Mr. Craig Alexander Collard · 128 employees · United States · https://www.herontx.com